Woman in white jacket administers a single precise dose from an Aptar Unidose liquid nasal spray device zoom view

Integrated Nasal Development Services

Aptar Pharma is a market leader with a wide range of drug delivery systems for nasal devices. But how do you bring a new nasal drug device combination product to market? Aptar Pharma knows.

We don’t just make some of the most advanced and proven nasal drug delivery systems on the market, but we also offer comprehensive nasal system development services that help our customers get to market faster. These services include specialized analytical, regulatory, and human factors support that can derisk and accelerate your nasal drug development project all the way to commercialization and beyond.

Aptar Pharma Integrated Support Services for Device Development

Development Services

As nasal spray products are drug device combinations, we develop customer products with the device and formulation in mind. We work with customers to help them develop a product formulation for the right nasal device for the intended application and therapeutic area. Aptar Pharma offers its extensive range of nasal drug delivery technologies with custom or modified options. Device options can be for functional formulation delivery reasons or for marketing differentiation.

Our team at Nanopharm, an Aptar Pharma company, can develop custom formulations optimized for use in the selected devices. With unrivalled knowledge of device capabilities, combined with our nasal drug delivery formulation expertise, Aptar Pharma can effectively and efficiently support the development of robust and compliant nasal formulations that meet your drug-device combination product’s requirements. All this support can be provided with data generated from specialized analytical testing, and computational pharmaceutics capabilities of Nanopharm including nasal cavity in-vivo models.

Analytical Services

Nasal drug products can require unique and specialized testing to fully characterize nasal drug delivery products. Aptar Pharma, combined with Nanopharm, offer specialized analytical capabilities to cover the full range of analytical services required. Our Nanopharm team offers formulation development services for nasal spray liquids or powders. They also offer leading edge computational pharmaceutics capabilities to understand critical parameters like regional deposition, permeation rates, absorption kinetics and nasal drug delivery targeting.

With a unique 3D nasal cavity in-vitro modelling system, Aptar Pharma can consistently measure and quantify drug deposition in discrete regions in the nasal cavity. We also offer unique and specialized techniques for alternative bioequivalence (MDRS). Aptar Pharma’s analytical service teams, can develop and validate cGMP test methods, run routine analytical testing for clinical and commercial batch release, as well as generate data forming part of the regulatory submission (ie In-vitro Bioequivalence (IVBE), Chemistry, Manufacturing and Controls (CMC), and drug product characterization (DPC) as per regulatory guidelines. Aptar Pharma services have one of the most comprehensive analytical testing capabilities for nasal products found anywhere.

Clinical Trials Support

When a nasal spray product is being developed, our customers rely on us for cGMP production of nasal drug delivery technologies, representative of the commercial device, to support their clinical trials. Our network of partnered CDMOs can be utilized to manufacture the drug device combination product in cGMP facilities that meet regulatory requirements.

Human Factor Testing & Services

Aptar Pharma’s Noble group provides Human Factors testing and services (HF+) to help customers to evaluate the overall usability, and patient preferences of self-administered drugs delivered with a nasal device. We do this by performing formative and validation studies with patients to U.S. FDA and EMEA guidelines, extending to regulatory strategy and submission support.

Noble can also perform market studies for training and onboarding tactics supporting stakeholder needs and market expectations. As customer’s progress to commercial scale-up, Noble is there developing custom training devices, literature, and training to make your new nasal product a success as you enter the market and post launch.

Regulatory Support

Aptar Pharma brings over 70 years of experience to every customer project. Globally, Aptar Pharma has worked with over 1,500 customers, on over 900 marketed drug products including 800 approved prescription drugs all using Aptar Pharma’s technology systems. With over 280 market references for nasal products, we have the ability to advance and support the launch of products in this specialty area.

This level of success has also generated a great deal of specialized regulatory knowledge within our organization and is shared with our customers. You have access to Aptar Pharma’s quality, design and regulatory support teams with decades of experience in advancing customer nasal products to commercialization. Drug Device combination regulations continue to evolve, and more requirements and guidance is expected in the near future. Our experts can offer regulatory support packages and direct one-on-one specialist support to guide customers through the complex regulatory process to address Drug-Device Combination, Human Factor, Reliability and Post Market Surveillance requirements. Aptar Pharma’s experience makes us an ideal partner for your nasal drug delivery products.

Patient Onboarding Services

When patients start using devices that contain Aptar Pharma’s nasal technology in clinical trials or after they are commercialized, our customers look to Noble (an Aptar Pharma company) for onboarding support. The team at Noble develops optimized onboarding tactics and best-in-class training programs through market studies to ensure all stakeholder and market expectations are met. Through primary stakeholder research, critical parameters of onboarding programs are identified and optimized. Onboarding is supported with appropriate training devices, literature and materials, helping patients to use the devices correctly and effectively.

Supply of Systems for Devices

Aptar Pharma operates a global network of manufacturing facilities that can produce our nasal drug delivery systems, scaled to every need, whether it be clinical or commercial. Furthermore, our Digital Health offering can seamlessly add digital connectivity, data and automation features to many of the devices. With a global distribution network and offices in many countries, Aptar Pharma can supply its advanced nasal technology anywhere in the world. Security of supply combined with unparalleled support to advance customer products through the complexities of drug device combination product regulations makes Aptar Pharma a clear leader in nasal drug delivery systems.

Aptar Pharma Support Services – Integrated Nasal Systems

Aptar Pharma has developed an integrated service offering to support the development of new nasal drug delivery products around their extensive range of nasal drug delivery products. As the product owner, you just need to start with an idea. The next great nasal spray product.

Once you’ve discovered and made your molecule, Aptar Pharma is well positioned to support you through the rest of the process so you can focus on your core capabilities. Advancing your product through clinical trials, seeking approval, and commercializing it, so it can reach the patients that need it most. And as your proven partner in nasal development, Aptar Pharma’s services support integrated nasal device development making achieving your goals a whole lot simpler.

Nasal Product Solutions

Product Filters

Done
Filter

Recently Published Resources

26 Feb 2024

Intranasal Delivery of Monoclonal Antibodies via Dry Powder

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
2 Feb 2024

Systemic Nasal Drug Delivery for CNS Diseases and Beyond

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Market Insights, Product Solutions

Read More
30 Jan 2024

Nanoparticle Formulation Strategies for Intranasal Drug Delivery

Publications, Pharmaceutical, Device Innovations, Market Insights, Product Solutions

Read More
3 Jan 2024

Feasibility of Intranasal Delivery of Thin-Film Freeze-Dried Monoclonal Antibodies

Publications, Pharmaceutical, Innovation & Insights, Device Innovations, Product Solutions

Read More
1 2 3 24